Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Brämswig, K; Ploner, F; Martel, A; Bauernhofer, T; Hilbe, W; Kühr, T; Leitgeb, C; Mlineritsch, B; Petzer, A; Seebacher, V; Stöger, H; Girschikofsky, M; Hochreiner, G; Ressler, S; Romeder, F; Wöll, E; Brodowicz, T.
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
Anticancer Drugs. 2014; 25(7):848-853
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Bauernhofer Thomas
Ploner Ferdinand
Stoeger Herbert
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Therapeutic options for patients with advanced pretreated soft tissue sarcomas are limited. However, in this setting, sorafenib has shown promising results. We reviewed the data of 33 patients with soft tissue sarcoma treated with sorafenib within a named patient program in Austria. Twelve physicians from eight different hospitals provided records for the analysis of data. Among the 33 patients, the predominant histological subtype of sarcoma was leiomyosarcoma (n=18, 55%). Other subtypes were represented by only one or two cases. Fifteen patients presented with metastases at the time of diagnosis. Another 17 patients developed metastases later in the course of the disease (data on one patient are missing). Most of the 33 patients had undergone resection of the primary (n=29, 88%) and half of the patients had received radiotherapy (n=17, 52%). Chemotherapy for metastatic disease had been administered to 30 patients (91%). The majority had received two or more regimens of chemotherapy (n=25, 76%) before sorafenib treatment. The use of sorafenib resulted in a median time to treatment failure of 92 days in patients with leiomyosarcoma and 45 days in patients with other histological subtypes. One-third of the patients derived benefits from treatment: four patients were documented with partial response and six with stabilized disease. In terms of treatment-related toxicity, skin problems of various degrees and gastrointestinal disturbances were frequently reported. In this retrospective analysis of heavily pretreated patients with advanced soft tissue sarcomas, sorafenib was associated with some antitumor activity and an acceptable toxicity profile.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Female -
Humans -
Leiomyosarcoma - drug therapy
Leiomyosarcoma - pathology
Male -
Middle Aged -
Neoplasm Metastasis -
Niacinamide - adverse effects
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Phenylurea Compounds - adverse effects
Phenylurea Compounds - therapeutic use
Retrospective Studies -
Soft Tissue Neoplasms - drug therapy
Soft Tissue Neoplasms - pathology
Young Adult -

Find related publications in this database (Keywords)
chemotherapy
leiomyosarcoma
sarcoma
sorafenib
© Meduni Graz Impressum